Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, aggressive B cell non-Hodgkin’s lymphoma of the body cavities with malignant effusions. The prognosis is poor, and no optimal treatment has been established. CD38 is a type II transmembrane glycoprotein known to overexpress in multiple myeloma (MM). Daratum...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2022-05, Vol.71 (5), p.1017-1031
Hauptverfasser:	Panaampon, Jutatip, Kariya, Ryusho, Okada, Seiji
Format:	Artikel
Sprache:	eng
Schlagworte:	ADP-ribosyl Cyclase 1 Animals Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibody-Dependent Cell Cytotoxicity Antineoplastic Agents - therapeutic use Cancer Research CD16 antigen CD38 antigen Cell death Cytolysis Cytotoxicity Effusion Humans Immunology Immunotherapy Lymphoma Lymphoma, Primary Effusion - drug therapy Macrophages Medicine Medicine & Public Health Mice Monoclonal antibodies Monocytes Multiple Myeloma Natural killer cells Non-Hodgkin's lymphoma Oncology Original Original Article Phagocytosis Primary effusion lymphoma Targeted cancer therapy Tumors Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!